Background: Osteoporosis increases the risk of fractures and mortality, particularly in the elderly population. However, prescribing antiresorptive medication to elderly patients with osteoporosis is complex. The benefit-risk ratio should be considered for all patients but can be particularly challenging in older individuals due to factors like comorbidities, polypharmacy, fall risk, and potential rare side effects of long-term treatment. Summary: We reviewed the efficacy and safety of antiresorptive treatments, including calcium and vitamin D supplementation, in elderly patients by evaluating published trials, reviews, and meta-analyses. Our findings confirm that antiresorptive treatment for osteoporosis is both effective and safe in the elderly population. Key Messages: One key challenge is ensuring compliance, which can be difficult for some elderly patients. In such cases, intravenously or subcutaneously administered antiresorptive treatment should be considered to improve adherence and overall treatment compliance.

1.
Salari
N
,
Darvishi
N
,
Bartina
Y
,
Larti
M
,
Kiaei
A
,
Hemmati
M
, et al
.
Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis
.
J Orthop Surg Res
.
2021
;
16
(
1
):
669
.
2.
Tran
T
,
Bliuc
D
,
Hansen
L
,
Abrahamsen
B
,
van den Bergh
J
,
Eisman
JA
, et al
.
Persistence of excess mortality following individual nonhip fractures: a relative survival analysis
.
J Clin Endocrinol Metab
.
2018
;
103
(
9
):
3205
14
.
3.
Abrahamsen
B
,
Nissen
N
,
Hermann
AP
,
Hansen
B
,
Bärenholdt
O
,
Vestergaard
P
, et al
.
When should densitometry be repeated in healthy peri- and postmenopausal women: the Danish osteoporosis prevention study
.
J Bone Miner Res
.
2002
;
17
(
11
):
2061
7
.
4.
Kanis
JA
,
Johnell
O
,
Oden
A
,
Dawson
A
,
De Laet
C
,
Jonsson
B
.
Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds
.
Osteoporos Int
.
2001
;
12
(
12
):
989
95
.
5.
Ziegenhain
F
,
Mittlmeier
AS
,
Pape
HC
,
Neuhaus
V
,
Canal
C
.
Influence of age on outcome following rib fractures: a case-control analysis
.
Geriatr Orthop Surg Rehabil
.
2024
;
15
:
21514593241280879
.
6.
Wu
C-Y
,
Tsai
C-F
,
Hsu
Y-H
,
Yang
H-Y
.
Exploring mortality risk factors and specific causes of death within 30 days after hip fracture hospitalization
.
Sci Rep
.
2024
;
14
(
1
):
27544
.
7.
Azevedo
SF
,
Mazeda
C
,
Silva
SP
,
Barcelos
A
.
Two-year mortality predictors in fragility fractures: a medical records review study
.
J Clin Rheumatol
.
2024
;
30
(
6
):
239
42
.
8.
Miller
PD
.
Underdiagnosis and undertreatment of osteoporosis: the battle to be won
.
J Clin Endocrinol Metab
.
2016
;
101
(
3
):
852
9
.
9.
Vestergaard
P
,
Rejnmark
L
,
Mosekilde
L
.
Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark
.
Osteoporos Int
.
2005
;
16
(
2
):
134
41
.
10.
McCloskey
E
,
Rathi
J
,
Heijmans
S
,
Blagden
M
,
Cortet
B
,
Czerwinski
E
, et al
.
The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study
.
Osteoporos Int
.
2021
;
32
(
2
):
251
9
.
11.
Chapuy
MC
,
Arlot
ME
,
Duboeuf
F
,
Brun
J
,
Crouzet
B
,
Arnaud
S
, et al
.
Vitamin D3 and calcium to prevent hip fractures in elderly women
.
N Engl J Med
.
1992
;
327
(
23
):
1637
42
.
12.
Eastell
R
,
Rosen
CJ
,
Black
DM
,
Cheung
AM
,
Murad
MH
,
Shoback
D
.
Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline
.
J Clin Endocrinol Metab
.
2019
;
104
(
5
):
1595
622
.
13.
Shah
VP
,
Nayfeh
T
,
Alsawaf
Y
,
Saadi
S
,
Farah
M
,
Zhu
Y
, et al
.
A systematic review supporting the Endocrine Society clinical practice guidelines on vitamin D
.
J Clin Endocrinol Metab
.
2024
;
109
(
8
):
1961
74
.
14.
Cameron
ID
,
Dyer
SM
,
Panagoda
CE
,
Murray
GR
,
Hill
KD
,
Cumming
RG
, et al
.
Interventions for preventing falls in older people in care facilities and hospitals
.
Cochrane Database Syst Rev
.
2018
;
9
(
9
):
CD005465
.
15.
Tang
BMP
,
Eslick
GD
,
Nowson
C
,
Smith
C
,
Bensoussan
A
.
Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis
.
Lancet
.
2007
;
370
(
9588
):
657
66
.
16.
Oda
T
,
Jödicke
AM
,
Robinson
DE
,
Delmestri
A
,
Keogh
RH
,
Prieto-Alhambra
D
.
Oral bisphosphonates are associated with increased risk of severe acute kidney injury in elderly patients with complex health needs: a self-controlled case series in the United Kingdom
.
J Bone Miner Res
.
2022
;
37
(
7
):
1270
8
.
17.
Bauer
DC
,
Black
DM
,
Dell
R
,
Fan
B
,
Smith
CD
,
Ernst
MT
, et al
.
Bisphosphonate use and risk of atypical femoral fractures: a Danish case-cohort study with blinded radiographic review
.
J Clin Endocrinol Metab
.
2024
;
109
(
11
):
e2141
50
.
18.
Black
DM
,
Geiger
EJ
,
Eastell
R
,
Vittinghoff
E
,
Li
BH
,
Ryan
DS
, et al
.
Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates
.
N Engl J Med
.
2020
;
383
(
8
):
743
53
.
19.
Black
DM
,
Reiss
TF
,
Nevitt
MC
,
Cauley
J
,
Karpf
D
,
Cummings
SR
.
Design of the fracture intervention trial
.
Osteoporos Int
.
1993
;
3
(
Suppl 3
):
S29
39
.
20.
Bone
HG
,
Downs
RW
,
Tucci
JR
,
Harris
ST
,
Weinstein
RS
,
Licata
AA
, et al
.
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers
.
J Clin Endocrinol Metab
.
1997
;
82
(
1
):
265
74
.
21.
Ensrud
KE
,
Black
DM
,
Palermo
L
,
Bauer
DC
,
Barrett-Connor
E
,
Quandt
SA
, et al
.
Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial
.
Arch Intern Med
.
1997
;
157
(
22
):
2617
24
.
22.
Hochberg
MC
,
Thompson
DE
,
Black
DM
,
Quandt
SA
,
Cauley
J
,
Geusens
P
, et al
.
Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures
.
J Bone Miner Res
.
2005
;
20
(
6
):
971
6
.
23.
Axelsson
KF
,
Wallander
M
,
Johansson
H
,
Lundh
D
,
Lorentzon
M
.
Hip fracture risk and safety with alendronate treatment in the oldest-old
.
J Intern Med
.
2017
;
282
(
6
):
546
59
.
24.
Välimäki
MJ
,
Farrerons-Minguella
J
,
Halse
J
,
Kröger
H
,
Maroni
M
,
Mulder
H
, et al
.
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial
.
Clin Ther
.
2007
;
29
(
9
):
1937
49
.
25.
Boonen
S
,
McClung
MR
,
Eastell
R
,
El-Hajj Fuleihan
G
,
Barton
IP
,
Delmas
P
.
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old
.
J Am Geriatr Soc
.
2004
;
52
(
11
):
1832
9
.
26.
McClung
MR
,
Geusens
P
,
Miller
PD
,
Zippel
H
,
Bensen
WG
,
Roux
C
, et al
.
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group
.
N Engl J Med
.
2001
;
344
(
5
):
333
40
.
27.
Reginster
J
,
Minne
HW
,
Sorensen
OH
,
Hooper
M
,
Roux
C
,
Brandi
ML
, et al
.
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group
.
Osteoporos Int
.
2000
;
11
(
1
):
83
91
.
28.
Delmas
PD
,
Recker
RR
,
Chesnut
CH
,
Skag
A
,
Stakkestad
JA
,
Emkey
R
, et al
.
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study
.
Osteoporos Int
.
2004
;
15
(
10
):
792
8
.
29.
Chesnut
CH
,
Skag
A
,
Christiansen
C
,
Recker
R
,
Stakkestad
JA
,
Hoiseth
A
, et al
.
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
.
J Bone Miner Res
.
2004
;
19
(
8
):
1241
9
.
30.
Ettinger
MP
,
Felsenberg
D
,
Harris
ST
,
Wasnich
R
,
Skag
A
,
Hiltbrunner
V
, et al
.
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age
.
J Rheumatol
.
2005
;
32
(
10
):
1968
74
.
31.
Black
DM
,
Delmas
PD
,
Eastell
R
,
Reid
IR
,
Boonen
S
,
Cauley
JA
, et al
.
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
.
N Engl J Med
.
2007
;
356
(
18
):
1809
22
.
32.
Lyles
KW
,
Colón-Emeric
CS
,
Magaziner
JS
,
Adachi
JD
,
Pieper
CF
,
Mautalen
C
, et al
.
Zoledronic acid and clinical fractures and mortality after hip fracture
.
N Engl J Med
.
2007
;
357
(
18
):
1799
809
.
33.
Reid
IR
,
Black
DM
,
Eastell
R
,
Bucci-Rechtweg
C
,
Su
G
,
Hue
TF
, et al
.
Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams
.
J Clin Endocrinol Metab
.
2013
;
98
(
2
):
557
63
.
34.
Boonen
S
,
Black
DM
,
Colón-Emeric
CS
,
Eastell
R
,
Magaziner
JS
,
Eriksen
EF
, et al
.
Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older
.
J Am Geriatr Soc
.
2010
;
58
(
2
):
292
9
.
35.
Cummings
SR
,
San Martin
J
,
McClung
MR
,
Siris
ES
,
Eastell
R
,
Reid
IR
, et al
.
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
.
N Engl J Med
.
2009
;
361
(
8
):
756
65
.
36.
Boonen
S
,
Adachi
JD
,
Man
Z
,
Cummings
SR
,
Lippuner
K
,
Törring
O
, et al
.
Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk
.
J Clin Endocrinol Metab
.
2011
;
96
(
6
):
1727
36
.
37.
McClung
MR
,
Boonen
S
,
Törring
O
,
Roux
C
,
Rizzoli
R
,
Bone
HG
, et al
.
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis
.
J Bone Miner Res
.
2012
;
27
(
1
):
211
8
.
38.
Jeong
C
,
Ha
J
.
The effect of denosumab on bone mass in super elderly patients
.
J Bone Metab
.
2020
;
27
(
2
):
119
24
.
39.
Yoon
S-H
,
Kim
K
,
Kim
K-C
.
The effect of denosumab in elderly patients regarding bone density and fracture risk
.
J Bone Metab
.
2023
;
30
(
3
):
275
82
.
40.
Jackson
RD
,
LaCroix
AZ
,
Gass
M
,
Wallace
RB
,
Robbins
J
,
Lewis
CE
, et al
.
Calcium plus vitamin D supplementation and the risk of fractures
.
N Engl J Med
.
2006
;
354
(
7
):
669
83
.
41.
Radford
LT
,
Bolland
MJ
,
Mason
B
,
Horne
A
,
Gamble
GD
,
Grey
A
, et al
.
The Auckland calcium study: 5-year post-trial follow-up
.
Osteoporos Int
.
2014
;
25
(
1
):
297
304
.
42.
Thiele
I
,
Linseisen
J
,
Meisinger
C
,
Schwab
S
,
Huth
C
,
Peters
A
, et al
.
Associations between calcium and vitamin D supplement use as well as their serum concentrations and subclinical cardiovascular disease phenotypes
.
Atherosclerosis
.
2015
;
241
(
2
):
743
51
.
43.
Bolland
MJ
,
Grey
A
,
Avenell
A
,
Gamble
GD
,
Reid
IR
.
Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis
.
BMJ
.
2011
;
342
:
d2040
.
44.
Cecilia
D
,
Jódar
E
,
Fernández
C
,
Resines
C
,
Hawkins
F
.
Effect of alendronate in elderly patients after low trauma hip fracture repair
.
Osteoporos Int
.
2009
;
20
(
6
):
903
10
.
45.
Cummings
SR
,
Black
DM
,
Thompson
DE
,
Applegate
WB
,
Barrett-Connor
E
,
Musliner
TA
, et al
.
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial
.
JAMA
.
1998
;
280
(
24
):
2077
82
.
46.
Reid
IR
,
Horne
AM
,
Mihov
B
,
Stewart
A
,
Garratt
E
,
Wong
S
, et al
.
Fracture prevention with zoledronate in older women with osteopenia
.
N Engl J Med
.
2018
;
379
(
25
):
2407
16
.
47.
Reid
IR
,
Horne
AM
,
Mihov
B
,
Stewart
A
,
Garratt
E
,
Wiessing
KR
, et al
.
Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial
.
J Intern Med
.
2019
;
286
(
2
):
221
9
.
48.
Abrahamsen
B
,
Eiken
P
,
Prieto-Alhambra
D
,
Eastell
R
.
Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study
.
BMJ
.
2016
;
353
:
i3365
.
49.
Khan
AA
,
Morrison
A
,
Hanley
DA
,
Felsenberg
D
,
McCauley
LK
,
O’Ryan
F
, et al
.
Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus
.
J Bone Miner Res
.
2015
;
30
(
1
):
3
23
.
50.
Zullo
AR
,
Lee
Y
,
Lary
C
,
Daiello
LA
,
Kiel
DP
,
Berry
SD
.
Comparative effectiveness of denosumab, teriparatide, and zoledronic acid among frail older adults: a retrospective cohort study
.
Osteoporos Int
.
2021
;
32
(
3
):
565
73
.
51.
Greenspan
SL
,
Perera
S
,
Haeri
NS
,
Nace
DA
,
Resnick
NM
.
Denosumab for osteoporosis in older adults in long-term care: a randomized trial
.
J Am Geriatr Soc
.
2025
;
73
(
2
):
445
57
.
52.
Chen
J
,
Smerdely
P
.
Hypocalcaemia after denosumab in older people following fracture
.
Osteoporos Int
.
2017
;
28
(
2
):
517
22
.
53.
Broadwell
A
,
Chines
A
,
Ebeling
PR
,
Franek
E
,
Huang
S
,
Smith
S
, et al
.
Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease
.
J Clin Endocrinol Metab
.
2021
;
106
(
2
):
397
409
.
54.
Nayak
S
,
Roberts
MS
,
Greenspan
SL
.
Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment
.
PLoS One
.
2012
;
7
(
3
):
e32879
.
55.
Pham
AN
,
Datta
SK
,
Weber
TJ
,
Walter
LC
,
Colón-Emeric
CS
.
Cost-effectiveness of oral bisphosphonates for osteoporosis at different ages and levels of life expectancy
.
J Am Geriatr Soc
.
2011
;
59
(
9
):
1642
9
.
56.
Ito
K
.
Cost-effectiveness of single-dose zoledronic acid for nursing home residents with osteoporosis in the USA
.
BMJ Open
.
2018
;
8
(
9
):
e022585
.
57.
Akehurst
R
,
Brereton
N
,
Ariely
R
,
Lusa
T
,
Groot
M
,
Foss
P
, et al
.
The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands
.
J Med Econ
.
2011
;
14
(
1
):
53
64
.
58.
Fardellone
P
,
Cortet
B
,
Legrand
E
,
Bresse
X
,
Bisot-Locard
S
,
Vigneron
AM
, et al
.
Cost-effectiveness model of using zoledronic acid once a year versus current treatment strategies in postmenopausal osteoporosis
.
Joint Bone Spine
.
2010
;
77
(
1
):
53
7
.
59.
Hiligsmann
M
,
Reginster
J-Y
.
Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
.
Bone
.
2010
;
47
(
1
):
34
40
.
60.
Mori
T
,
Crandall
CJ
,
Ganz
DA
.
Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan
.
Osteoporos Int
.
2017
;
28
(
5
):
1733
44
.
61.
Silverman
S
,
Agodoa
I
,
Kruse
M
,
Parthan
A
,
Orwoll
E
.
Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective
.
J Osteoporos
.
2015
;
2015
:
627631
.
62.
Händel
MN
,
Cardoso
I
,
von Bülow
C
,
Rohde
JF
,
Ussing
A
,
Nielsen
SM
, et al
.
Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials
.
BMJ
.
2023
;
381
:
e068033
.
63.
Clemens
KK
,
Jeyakumar
N
,
Ouédraogo
AM
,
Thain
J
,
Khan
T
.
Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study
.
Arch Osteoporos
.
2020
;
15
(
1
):
133
.
You do not currently have access to this content.